PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - New Market Report

From: Fast Market Research, Inc.
Published: Wed Mar 30 2016

Congenital hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.

GlobalData estimates the 2014 sales for recombinant hemophilia A and B markets at approximately $5.38 billion across the 7MM+A covered in this report. The market is expected to reach $6.25 billion in 2024 at a CAGR of 1.52%. This growth will be mainly driven by an increasing use of routine prophylaxis and a greater use of recombinant products in place of plasma-derived therapies.

Full Report Details at

The hemophilia recombinant treatment pipeline is strong, and crowded with multiple long-acting recombinant clotting factors; however, GlobalData expects a lack of initiative for hemophilia A patients to switch to long-acting rFVIII, and a limited scope for premium pricing for new agents, restraining the market growth. Overall, Baxalta is expected to remain as the market leader in the hemophilia space throughout the forecast period, dominating the market with its current gold standard therapy for hemophilia A, Advate, supported by the launch its of pegylated rFVIII, Adynovate.

Key Questions Answered in this Report

* What will be the impact of the new long-acting rFVIII and rFIX products in the hemophilia market sales? Led by Biogen's Eloctate and Alprolix, moderate and high rates of adoption of the long-acting rFVIII and rFIX therapies, respectively, are expected.
* With the growing importance of long-acting Factors, what are the strategies of the companies that have short-acting assets to remain competitive? What are the other approaches that new entrants employ?
* Prevention of inhibitor formation remains as a major unmet need in the hemophilia space. What are the other unmet needs and opportunities in the hemophilia market?

Key Report Findings

* One of the main drivers of the expansion of the hemophilia recombinant market will be the increasing use of routine prophylaxis in pediatric and adult hemophilia A and B patients. Prophylactic regimens have demonstrated improvements in the prevention of bleeding episodes and joint damage. In the 7MM, routine prophylaxis is the standard of care for severe hemophilia patients.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024
- PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »